摘要
目的探讨非小细胞肺癌(NSCLC)患者血清中miR-125b的表达水平变化及其在NSCLC辅助诊断和疗效评估中的临床应用价值。方法采用实时荧光定量PCR法检测102例NSCLC患者、45例肺部良性疾病患者和42例健康对照者血清中miR-125b的表达量。结果 NSCLC患者化疗前血清中miR-125b的表达水平明显高于健康人和肺部良性疾病组(P<0.05);血清miR-125b在Ⅲ期+Ⅳ期中的表达水平显著高于Ⅰ期+Ⅱ期(P<0.01)。与化疗前比较,晚期NSCLC患者化疗2个周期后,血清中miR-125b的表达量明显降低(P<0.05)。结论血清miR-125b的检测对于NSCLC的辅助诊断和化疗疗效评价有一定的临床应用价值。
Objective To evaluate the serum level of miR-125 bin non-small cell lung cancer（NSCLC）patients and its clinical significance for diagnosis and evaluating efficacy of chemotherapy of NSCLC.Methods Real-time quantitative PCR method was used to examine the levels of serum miR-125 bin 102patients with NSCLC,45 patients with lung benign disease and 42 healthy controls.Results The level of serum miR-125 bin patients with NSCLC was significantly higher than that of patients with lung benign disease and healthy controls（P〈0.05）;The level of serum miR-125 bwas found to be significantly higher in stagesⅢ and IV than stagesⅠ and Ⅱ（P〈0.01）;The serum miR-125 blevel of advanced NSCLC patients after two treatment course was significantly lower than that of pre-chemotherapy（P〈0.05）.Conclusion Detection of serum miR-125 bhas certain clinical values for diagnosis and evaluating efficacy of chemotherapy of NSCLC.
出处
《国际检验医学杂志》
CAS
2015年第14期2005-2006,2008,共3页
International Journal of Laboratory Medicine
关键词
聚合酶链反应
非小细胞肺癌
微小RNA
辅助诊断
疗效评估
polymerase chain reaction
non-small cell lung cancer
microRNA
diagnosis
evaluating efficacy
